‌

US Patent 11351232 Albumin-free botulinum toxin formulations

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Revance Therapeutics, Inc.

Current Assignee

Revance Therapeutics, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

June 7, 2022

Patent Application Number

16175434

Date Filed

October 30, 2018

Patent Citations

US Patent 10201594 Compositions and methods for safe treatment of rhinitis

US Patent 10285941 Amphiphilic entity nanoparticles

US Patent 10549042 Botulinum toxin prefilled glass syringe

US Patent 10576034 Botulinum nanoemulsions

US Patent 10561604 Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose

US Patent 10744078 Compositions and methods for topical application and transdermal delivery of botulinum toxins

US Patent 10080786 Methods for treating pain by topical application and transdermal delivery of botulinum toxin

US Patent 10105421 Therapeutic composition with a botulinum neurotoxin

...

Patent Citations Received

US Patent 11680087 None

0

Patent Primary Examiner

Nita M. Minnifield

This invention relates to

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11351232 Albumin-free botulinum toxin formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool